Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Case report

Pulmonary fibrosis in dyskeratosis congenita: a case report with a PRISMA-compliant systematic review

Authors: Ping Wang, Zuojun Xu

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

Dyskeratosis congenita (DC) is a rare genetic disorder of poor telomere maintenance. Pulmonary fibrosis (PF) related to DC is rarely reported.

Case presentation

A 23-year-old student presented with a four-year history of progressive cough and exertional dyspnea. Physical examination was remarkable for typical mucocutaneous abnormalities. Chest computerized tomography scan revealed interstitial fibrosis. Testing of peripheral blood leukocytes confirmed that his telomeres were 30th percentile of age-matched controls. A heterozygous missense mutation located in exon 22 of PARN gene was identified in the patient by whole exome sequencing. The patient refused danazol therapy and lung transplantation, and died of respiratory failure 2 years later. In addition, this case and 26 reported cases of DC-related PF identified through the comprehensive search of PubMed, Web of Science, WANFANG and CNKI were reviewed. Later-onset PF was observed in 11 patients (40.7%). Radiological usual interstitial pneumonia (UIP) pattern or possible UIP pattern was noted only in half of patients. However, histopathological UIP or probable UIP patterns were found in 63.6% of patients. Age at bone marrow failure (BMF) and the frequency of normal to mild thrombocytopenia in later-onset patients was significantly higher than in early-onset patients (p = 0.017 and p = 0.021, respectively). Age at PF and age at BMF in DC patients with TERC/TERT variants was significantly higher than in those with TINF2 variants or DKC1/NHP2 variants (p = 0.004 and p = 0.003, respectively). The patients with TERT/TERC/RTEL1/PARN variants had a significantly better transplant-free survival than those with TINF2 variants or DKC1/NHP2 variants (p < 0.05). Patients who underwent surgical lung biopsy had significantly worse transplant-free survival than those without lung biopsy (p = 0.042). Worse survival was found in patients with immunosuppression therapy than in those without (p = 0.012).

Conclusions

It is common for DC-associated PF to occur later in life without significant hematological manifestations. Mutations in the genes encoding different components of the telomere maintenance pathway were associated with clinical phenotypes and prognosis. PF caused by DC should be kept in mind by clinicians in the differential diagnosis of patients with unexplained PF and should be excluded before diagnostic surgical lung biopsy is undertaken or empirical immunosuppression therapy is prescribed.
Appendix
Available only for authorised users
Literature
14.
go back to reference Zhang K, Li H, Lu R, Kong X, Bai Y, Jiang N, et al. A case report of pulmonary fibrosis complicating dyskeratosis congenita. Chin J Tubere Respir Dis. 2015;38(9):701–3. Zhang K, Li H, Lu R, Kong X, Bai Y, Jiang N, et al. A case report of pulmonary fibrosis complicating dyskeratosis congenita. Chin J Tubere Respir Dis. 2015;38(9):701–3.
16.
go back to reference Hisata S, Sakaguchi H, Kanegane H, Hidaka T, Shiihara J, Ichinose M, et al. A novel missense mutation of DKC1 in dyskeratosis congenita with pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(3):221–5.PubMed Hisata S, Sakaguchi H, Kanegane H, Hidaka T, Shiihara J, Ichinose M, et al. A novel missense mutation of DKC1 in dyskeratosis congenita with pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(3):221–5.PubMed
18.
go back to reference Utz JP, Ryu JH, Myers JL, Michels VV. Usual interstitial pneumonia complicating dyskeratosis congenita. Mayo Clin Proc. 2005;80(6):817–21.CrossRefPubMed Utz JP, Ryu JH, Myers JL, Michels VV. Usual interstitial pneumonia complicating dyskeratosis congenita. Mayo Clin Proc. 2005;80(6):817–21.CrossRefPubMed
19.
go back to reference Kilic S, Kose H, Ozturk H. Pulmonary involvement in a patient with dyskeratosis congenita. Pediatr Int. 2003;45(6):740–2.CrossRefPubMed Kilic S, Kose H, Ozturk H. Pulmonary involvement in a patient with dyskeratosis congenita. Pediatr Int. 2003;45(6):740–2.CrossRefPubMed
20.
go back to reference Safa WF, Lestringant GG, Frossard PM. X-linked dyskeratosis congenita: restrictive pulmonary disease and a novel mutation. Thorax. 2001;56(11):891–4.CrossRefPubMedPubMedCentral Safa WF, Lestringant GG, Frossard PM. X-linked dyskeratosis congenita: restrictive pulmonary disease and a novel mutation. Thorax. 2001;56(11):891–4.CrossRefPubMedPubMedCentral
21.
go back to reference Yabe M, Yabe H, Hattori K, Morimoto T, Hinohara T, Takakura I, et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19(4):389–92.CrossRefPubMed Yabe M, Yabe H, Hattori K, Morimoto T, Hinohara T, Takakura I, et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19(4):389–92.CrossRefPubMed
22.
go back to reference Imokawa S, Sato A, Toyoshima M, Yoshitomi A, Tamura R, Suda T, et al. Dyskeratosis congenita showing usual interstitial pneumonia. Intern Med. 1994;33(4):226–30.CrossRefPubMed Imokawa S, Sato A, Toyoshima M, Yoshitomi A, Tamura R, Suda T, et al. Dyskeratosis congenita showing usual interstitial pneumonia. Intern Med. 1994;33(4):226–30.CrossRefPubMed
23.
go back to reference Verra F, Kouzan S, Saiag P, Bignon J, de Cremoux H. Bronchoalveolar disease in dyskeratosis congenita. Eur Respir J. 1992;5(4):497–9.PubMed Verra F, Kouzan S, Saiag P, Bignon J, de Cremoux H. Bronchoalveolar disease in dyskeratosis congenita. Eur Respir J. 1992;5(4):497–9.PubMed
33.
go back to reference Justet A, Thabut G, Manali E, Molina Molina M, Kannengiesser C, Cadranel J, Cottin V, Gondouin A, Nunes H, Magois E, Tromeur C, Prevot G, Papiris S, Marchand-Adam S, Gamez AS, Reynaud-Gaubert M, Wemeau L, Crestani B, Borie R. Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. Eur Respir J. 2018;51(3):1701875. https://doi.org/10.1183/13993003.01875-2017.CrossRefPubMed Justet A, Thabut G, Manali E, Molina Molina M, Kannengiesser C, Cadranel J, Cottin V, Gondouin A, Nunes H, Magois E, Tromeur C, Prevot G, Papiris S, Marchand-Adam S, Gamez AS, Reynaud-Gaubert M, Wemeau L, Crestani B, Borie R. Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. Eur Respir J. 2018;51(3):1701875. https://​doi.​org/​10.​1183/​13993003.​01875-2017.CrossRefPubMed
Metadata
Title
Pulmonary fibrosis in dyskeratosis congenita: a case report with a PRISMA-compliant systematic review
Authors
Ping Wang
Zuojun Xu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01645-w

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.